PolyPEPI-SCoV-2 / Treos Bio - LARVOL DELTA

T cell immunity ameliorates COVID-19 disease severity and provides post-exposure prophylaxis after peptide-vaccination, in Syrian hamsters. (PubMed, Front Immunol) - "Here, we have assessed the kinetics of T cell responses and protective efficacy against severe COVID-19 in pre- and post-exposure settings, elicited by PolyPEPI-SCoV-2, a peptide based T cell vaccine...Still, peptide vaccination significantly reduced body weight loss (p<0.001), relative lung weight (p<0.05) and lung lesions (p<0.05), in both settings. Our study provides first proof of concept data on the contribution of T cell immunity on disease course and provide rationale for the use of T cell-based peptide vaccines against both novel SARS-CoV-2 variants and supports post-exposure prophylaxis as alternative vaccination strategy against COVID-19."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

A Peptide Vaccine Candidate Tailored to Individuals' Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects. (PubMed, Front Genet) - "PolyPEPI-SCoV-2 administered with Montanide ISA 51 VG generated robust, Th1-biased CD8, and CD4 T cell responses against all represented proteins, as well as binding antibodies upon subcutaneous injection into BALB/c and hCD34 transgenic mice modeling human immune system. These results have implications for the development of global, highly immunogenic, T cell-focused vaccines against various pathogens and diseases."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8